The impact of β-blockers on outcomes of immune checkpoint inhibitors therapy in advanced lung cancer: a multicenter real-world study
In stage-advanced lung cancer, BBs combined with ICIs were associated with improved ORR and prolonged PFS, but did not significantly improve OS. PFS and ORR benefits were also observed in patients with CVD or NSCLC. Further prospective studies are needed to validate these findings and clarify whether BBs directly contribute to ICIs' efficacy.
Authors
- Haitian Zhang (ORCID: https://orcid.org/0000-0002-1122-8647)
- Hongjin Shi
- Yitong Li (ORCID: https://orcid.org/0009-0003-9741-4436)
- Jilan Yang
- Guangming Wang (ORCID: https://orcid.org/0000-0002-9084-7867)
- Jinsong Zhang (ORCID: https://orcid.org/0000-0002-6457-0235)
- Yunxia Li (ORCID: https://orcid.org/0000-0002-2086-3415)
- Bing Hai (ORCID: https://orcid.org/0009-0005-1594-2441)
- Lingdan Chang
Institutions
- Yunnan University (CN)
- Kunming Medical University (CN)
- Second People's Hospital of Yunnan Province (CN)
- The First Hospital of Kunming (CN)
- Malaysia Theological Seminary (MY)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1693249
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00